SCHEMBL6239376

SCHEMBL6239376

CCCS(=O)(=O)NC1CCC=C1c1ccc(-c2cccc(NS(C)(=O)=O)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.47
KDM1A O60341 1/20 0.47
GRIA2 P42262 6/20 0.43
KCNH2 Q12809 4/20 0.43
TDP2 O95551 2/20 0.42
AAK1 Q2M2I8 2/20 0.42
GAK O14976 1/20 0.42
STK16 O75716 1/20 0.42
BMP2K Q9NSY1 1/20 0.42
BRD4 O60885 2/20 0.41
LMNA P02545 3/20 0.40
USP2 O75604 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6243998 0.94 KIF11 (0.46) KIF11KDM1AGRIA2KCNH2TDP2
SCHEMBL6246776 0.86 GRIA2 (0.44) GRIA2KCNH2AAK1GAKSTK16
SCHEMBL6243811 0.84 PSEN1 (0.45) KCNH2LMNAMEN1ALDH1A1KMT2A
SCHEMBL6245811 0.84 CA12 (0.39) TDP2AAK1GAKSTK16BMP2K
SCHEMBL6239372 0.83 GRIA2 (0.60) KIF11KDM1AGRIA2KCNH2TDP2
SCHEMBL6236867 0.81 ADAMTS4 (0.40) KDM1A
SCHEMBL6239215 0.80 GRIA2 (0.43) GRIA2KCNH2AAK1GAKSTK16
SCHEMBL6239214 0.78 CYP11B1 (0.40) CYP3A4CYP2C19
SCHEMBL6244084 0.78 CA12 (0.38) KCNH2AAK1GAKSTK16BMP2K
SCHEMBL6246324 0.78 PSEN1 (0.43) KCNH2LMNAMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395550-B1 CYCLOALKENYLSULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2005-06-29 EP disclosed
US-20040157817-A1 Cycloalkenylsulfonamide derivatives CANTELL BUDDY EUGENE (US) 2004-08-12 US disclosed
EP-1395550-A1 CYCLOALKENYLSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-03-10 EP disclosed
WO-2002098847-A1 CYCLOALKENYLSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157817-A1 Cycloalkenylsulfonamide derivatives GRIN2B, GRIN2A, GRIN1 KIF11 2947/4885KDM1A 3863/4885GRIA2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.